Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Novartis Ag (NVS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 200,933,232
  • Shares Outstanding, K 2,365,590
  • Annual Sales, $ 49,436 M
  • Annual Income, $ 6,712 M
  • 36-Month Beta 0.74
  • Price/Sales 4.14
  • Price/Cash Flow 17.82
  • Price/Book 2.87

Price Performance

See More
Period Period Low Period High Performance
1-Month
82.61 +4.30%
on 08/30/17
86.41 -0.29%
on 09/20/17
+2.65 (+3.17%)
since 08/22/17
3-Month
81.43 +5.81%
on 07/11/17
86.57 -0.47%
on 06/23/17
-0.18 (-0.21%)
since 06/22/17
52-Week
66.93 +28.73%
on 12/08/16
86.90 -0.85%
on 06/22/17
+4.13 (+5.03%)
since 09/22/16

Most Recent Stories

More News
Corporate News Blog - Novartis Receives EC's Approval for Rydapt; Set to Treat FLT3-Mutated Active Myeloid Leukemia

LONDON, UK / ACCESSWIRE / September 22, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Novartis AG (NYSE: NVS), following which we have published...

NVS : 86.16 (+1.44%)
Novartis and The Max Foundation transform pioneering cancer access program for people in lower-income countries

Novartis International AG / Novartis and The Max Foundation transform pioneering cancer access program for people in lower-income countries . Processed and transmitted by Nasdaq Corporate Solutions. The...

NVS : 86.16 (+1.44%)
4 Sell-Ranked Biotech Stocks with Falling Estimates to Avoid

Though the biotech industry is doing well, it's a good idea to avoid a few stocks in the industry which will not prove to be prudent additions to your portfolio.

URGN : 30.49 (+3.32%)
ABEO : 14.95 (-7.72%)
CLSD : 8.30 (+1.84%)
RETA : 31.75 (+0.41%)
NVS : 86.16 (+1.44%)
GILD : 83.27 (+0.79%)
RHHBY : 32.0200 (-0.06%)
KITE : 179.30 (-0.04%)
AMGN : 185.76 (-0.47%)
How is the Age-Related Macular Degeneration Space Faring Now?

The Age-Related Macular Degeneration (AMD) space has been in the spotlight of late due to a number of developments.

AGN : 204.65 (+0.98%)
OPHT : 2.69 (unch)
NVS : 86.16 (+1.44%)
RHHBY : 32.0200 (-0.06%)
REGN : 432.72 (-0.17%)
Mylan Down 24% Year to Date: What's Troubling the Stock?

Shares of Mylan N.V. (MYL) have declined 24.7% in the last six months compared to the industry's loss of 20%.

MYL : 31.30 (+0.19%)
NVS : 86.16 (+1.44%)
RHHBY : 32.0200 (-0.06%)
PFE : 35.96 (-0.03%)
Novartis Poised to Grow on Oncology Portfolio & Biosimilars

Novartis expects the next growth phase to begin in 2018 driven by Cosentyx Entresto, Kisqali and Kymriah.

NVS : 86.16 (+1.44%)
RHHBY : 32.0200 (-0.06%)
AMGN : 185.76 (-0.47%)
ALXN : 142.82 (-0.07%)
Pfizer's Sutent Label Expansion Gets Mixed FDA Committee View

Pfizer's (PFE) cancer drug Sutent gets a mixed opinion from an FDA advisory committee regarding a regulatory application, which was filed to expand its label.

BAYRY : 33.0300 (-0.09%)
NVO : 49.22 (+0.33%)
NVS : 86.16 (+1.44%)
PFE : 35.96 (-0.03%)
Novartis drug Rydapt(R) (midostaurin) receives EU approval for newly diagnosed FLT3-mutated acute myeloid leukemia (AML) and three types of advanced systemic mastocytosis (SM)

Novartis International AG / Novartis drug Rydapt(R) (midostaurin) receives EU approval for newly diagnosed FLT3-mutated acute myeloid leukemia (AML) and three types of advanced systemic mastocytosis...

NVS : 86.16 (+1.44%)
New analysis shows Entresto improved physical and social activity in patients with HFrEF

Novartis announced today results of a new post-hoc analysis, which found that Entresto® (sacubitril/valsartan) improved seven out of 10 types of physical and social activities for HFrEF patients, also...

NVS : 86.16 (+1.44%)
Novartis Announces Positive Data on Urticaria Drug Xolair

Novartis AG (NVS) announced new positive data on chronic spontaneous urticaria (CSU) drug Xolair from a phase IIIb study, OPTIMA.

NVS : 86.16 (+1.44%)
RHHBY : 32.0200 (-0.06%)
AMGN : 185.76 (-0.47%)
ADRO : 10.80 (-1.82%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Novartis AG is committed to improving health and well-being through innovative products and services. The company aspires to capture and hold a leadership position in all of their businesses with a strong, sustainable performance based on continuous innovation. Their long-term success is founded on...

See More

Support & Resistance

2nd Resistance Point 86.61
1st Resistance Point 86.38
Last Price 86.16
1st Support Level 85.89
2nd Support Level 85.63

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.